Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drastic fall of growth differentiation factor 15 in influenza encephalopathy.

Pediatrics international : official journal of the Japan Pediatric Society·2024
Same author

Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis.

Scientific reports·2022
Same author

Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease.

Advanced genetics (Hoboken, N.J.)·2022
Same author

BCS1L mutations produce Fanconi syndrome with developmental disability.

Journal of human genetics·2021
Same author

Temporal changes and control variables of growth differentiation factor 15 levels during the first week of life in hospitalised newborn infants.

Mitochondrion·2021
Same author

Mitochondrial DNA depletion syndrome with a mutation in SLC25A4 developing epileptic encephalopathy: A case report.

Brain & development·2021

Related Experiment Video

Updated: Jun 25, 2026

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

[L-arginine therapy on MELAS].

Yasutoshi Koga1

  • 1Department of Pediatrics and Child Health, Kurume University School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|February 10, 2009
PubMed
Summary

Juvenile Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is more severe with a poorer prognosis than adult-onset MELAS. L-arginine shows promise in treating stroke-like episodes in MELAS patients.

Area of Science:

  • Mitochondrial Medicine
  • Neurology
  • Genetics

Context:

  • Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a significant mitochondrial disorder.
  • The natural history and prognostic factors of MELAS remain incompletely understood.
  • Distinguishing between juvenile and adult-onset MELAS is crucial for understanding disease trajectory.

Purpose:

  • To elucidate the natural course of MELAS by analyzing a Japanese cohort.
  • To compare the clinical characteristics and outcomes of juvenile-onset versus adult-onset MELAS.
  • To investigate the therapeutic potential of L-arginine in managing MELAS-related stroke-like episodes.

Summary:

  • The Japanese Cohort study on MELAS identified distinct differences between juvenile (onset <18 years) and adult (onset >18 years) forms.

More Related Videos

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

Related Experiment Videos

Last Updated: Jun 25, 2026

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
04:12

Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma

Published on: January 19, 2024

  • Juvenile MELAS exhibits a significantly earlier age of onset, earlier age of death, and a 3.2 times higher mortality rate compared to adult MELAS.
  • Intravenous or oral administration of L-arginine, a nitric oxide precursor, demonstrated significant improvements in stroke-like symptoms and reduced their frequency and severity.

    • Impact:

    • This study highlights the more severe prognosis of juvenile MELAS, emphasizing the need for early intervention and tailored management strategies.
    • L-arginine therapy presents a promising treatment option for mitigating the debilitating stroke-like episodes characteristic of MELAS.
    • Findings contribute to a better understanding of MELAS natural history and potential therapeutic targets, improving patient outcomes.